Table 2.
Recipient and Donor Characteristics for HRT Recipients in the Subgroup With Severe Renal Dysfunction (eGFR <30 mL/min per 1.73 m2 or on dialysis; n=323), With or Without Concurrent KT
| HRT‐KT (n=76) | HRT Alone (n=247) | P Value | Missing Data | |
|---|---|---|---|---|
| Recipient characteristics | ||||
| Recipient age, y | 46 (33–56) | 41 (25–56) | 0.689 | 0 (0%) |
| Recipient weight, kg | 75 (63–88) | 72 (58–88) | 0.567 | 6 (2%) |
| Recipient female sex | 16 (21%) | 86 (35%) | 0.024 | 0 (0%) |
| Status 1A | 22 (29%) | 108 (46%) | 0.010 | 11 (3%) |
| Days spent on wait‐list | 84 (35–212) | 28 (5–140) | <0.001 | 4 (1%) |
| Years since first transplant | 10 (4–13) | 6 (0 to 10) | <0.001 | 6 (2%) |
| Indication for heart retransplant | 0.051 | 0 (0%) | ||
| Acute rejection | 3 (4%) | 18 (7%) | ||
| Chronic rejection | 6 (8%) | 16 (6%) | ||
| Coronary artery disease | 43 (57%) | 96 (39%) | ||
| Primary graft failure | 5 (7%) | 43 (17%) | ||
| Nonspecific graft failure | 4 (5%) | 22 (9%) | ||
| Other | 15 (20%) | 52 (21%) | ||
| Dialysis | 42 (58%) | 104 (46%) | 0.081 | 23 (7%) |
| Hypertension (data only available from 1994 to 2007) | 25 (63%) | 77 (44%) | 0.053 | 109 (34%) |
| Total bilirubin, mg/dL | 1.2 (0.6–1.4) | 2.6 (0.7–2.0) | 0.004 | 31 (10%) |
| Diabetes | 14 (20%) | 22 (11%) | 0.067 | 58 (18%) |
| Recipient CMV positive | 37 (55%) | 115 (74%) | 0.007 | 100 (40%) |
| Recipient inotrope use | 39 (51%) | 158 (64%) | 0.048 | 0 (0%) |
| ECMO support | 1 (1%) | 18 (7%) | 0.054 | 0 (0%) |
| Mechanical ventilation | 3 (4%) | 73 (30%) | <0.001 | 0 (0%) |
| Recipient PRA level >10% | 15 (22%) | 60 (27%) | 0.517 | 29 (9%) |
| Recipient PRA levels | 0.668 | 28 (9%) | ||
| ≤10% | 53 (78%) | 161 (73%) | ||
| 11% to 50% | 7 (10%) | 31 (14%) | ||
| >50% | 8 (12%) | 29 (13%) | ||
| Donor characteristics | ||||
| Donor age, y | 30 (20–41) | 28 (18–38) | 0.102 | 0 (0%) |
| Donor weight, kg | 78 (65–92) | 73 (61–89) | 0.118 | 3 (1%) |
| Donor female sex | 30 (39%) | 73 (30%) | 0.105 | 0 (0%) |
| Donor CMV positive | 43 (57%) | 151 (61%) | 0.455 | 1 (1%) |
| Donor CPR support | 6 (9%) | 6 (4%) | 0.115 | 84 (26%) |
| Donor inotrope use | 42 (55%) | 96 (39%) | 0.025 | 5 (2%) |
| Heart ischemic time, hours | 3.3 (2.6–3.8) | 3.3 (2.5–4.0) | 0.937 | 27 (8%) |
| Era of heart retransplant | <0.001 | 0 (0%) | ||
| 1987–1995 | 4 (5%) | 36 (15%) | ||
| 1996–2000 | 9 (12%) | 69 (28%) | ||
| 2001–2005 | 27 (36%) | 79 (32%) | ||
| 2006–2011 | 36 (47%) | 63 (26%) | ||
CMV indicates cytomegalovirus; CPR, cardiopulmonary resuscitation; ECMO, extracorporeal membrane oxygenation; eGFR, estimated glomerular filtration rate; HRT, heart retransplant; KT, kidney transplant; PRA, panel reactive antibody level; Status 1A, highest wait‐list urgency status.